<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>生物制药小编 | wechat-feeds</title><link>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</link><description>“新起点，再出发”——生物医药小编与您共同关注生物制药行业热点。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 18 Apr 2021 10:11:48 +0800</pubDate><image><url>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</url><title>生物制药小编 | wechat-feeds</title><link>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>诺华（Novartis）——天价药合理且合法？</title><link>https://mp.weixin.qq.com/s/dlvvGvoibZ3IulDMRVYTBw</link><description></description><content:encoded><![CDATA[诺华（Novartis）——天价药合理且合法？]]></content:encoded><pubDate>Sat, 17 Apr 2021 19:49:00 +0800</pubDate></item><item><title>买家团火热来袭：你的渠道够强吗？</title><link>https://mp.weixin.qq.com/s/JibfojDUsS3YGGFWI9YWFA</link><description></description><content:encoded><![CDATA[买家团火热来袭：你的渠道够强吗？]]></content:encoded><pubDate>Sat, 17 Apr 2021 19:49:00 +0800</pubDate></item><item><title>做中国生物医药的忠实记录者</title><link>https://mp.weixin.qq.com/s/UouMgDdStjrP8MN-NWRE5w</link><description></description><content:encoded><![CDATA[做中国生物医药的忠实记录者]]></content:encoded><pubDate>Sat, 17 Apr 2021 19:49:00 +0800</pubDate></item><item><title>双特异性抗体：on-target off-tumor毒性及克服策略</title><link>https://mp.weixin.qq.com/s/6mUjx3lHw4KivmuA3Ff-qQ</link><description></description><content:encoded><![CDATA[双特异性抗体：on-target off-tumor毒性及克服策略]]></content:encoded><pubDate>Fri, 16 Apr 2021 19:25:47 +0800</pubDate></item><item><title>佰傲严选：亮剑吧！您的分析仪器！</title><link>https://mp.weixin.qq.com/s/V6zouh-X1N5Ibti_CFabjQ</link><description></description><content:encoded><![CDATA[佰傲严选：亮剑吧！您的分析仪器！]]></content:encoded><pubDate>Fri, 16 Apr 2021 19:25:47 +0800</pubDate></item><item><title>杨森Bipod高通量双抗开发平台</title><link>https://mp.weixin.qq.com/s/T72LX0A-8FdxZUlB0myUHg</link><description></description><content:encoded><![CDATA[杨森Bipod高通量双抗开发平台]]></content:encoded><pubDate>Thu, 15 Apr 2021 17:06:00 +0800</pubDate></item><item><title>腺相关病毒载体AAVs的快速表征分析</title><link>https://mp.weixin.qq.com/s/RKdb8UjLGzgxYA-L9Jmc5w</link><description></description><content:encoded><![CDATA[腺相关病毒载体AAVs的快速表征分析]]></content:encoded><pubDate>Thu, 15 Apr 2021 17:06:00 +0800</pubDate></item><item><title>抓住质量管理“牛鼻子“，你在哪一段？</title><link>https://mp.weixin.qq.com/s/XNKKhoJ90bKZLW27qCdYaw</link><description></description><content:encoded><![CDATA[抓住质量管理“牛鼻子“，你在哪一段？]]></content:encoded><pubDate>Thu, 15 Apr 2021 17:06:00 +0800</pubDate></item><item><title>靶向CD36：肿瘤免疫疗法的新策略</title><link>https://mp.weixin.qq.com/s/Ph7R9gxecy4UuYRNvjKSaw</link><description></description><content:encoded><![CDATA[靶向CD36：肿瘤免疫疗法的新策略]]></content:encoded><pubDate>Wed, 14 Apr 2021 16:49:28 +0800</pubDate></item><item><title>重磅︱乐纯生物与雷诺丽特签署战略合作协议</title><link>https://mp.weixin.qq.com/s/hhJtdvF9j0BTvPsCKmfdsA</link><description></description><content:encoded><![CDATA[重磅︱乐纯生物与雷诺丽特签署战略合作协议]]></content:encoded><pubDate>Wed, 14 Apr 2021 16:49:28 +0800</pubDate></item><item><title>首个适应症刚获转正，FDA又加速批准Trodelvy第二个适应症--膀胱癌</title><link>https://mp.weixin.qq.com/s/sOGICs99bE5uF4l494H6oA</link><description></description><content:encoded><![CDATA[首个适应症刚获转正，FDA又加速批准Trodelvy第二个适应症--膀胱癌]]></content:encoded><pubDate>Wed, 14 Apr 2021 16:49:28 +0800</pubDate></item><item><title>抓住质量管理“牛鼻子“，你在哪一段？</title><link>https://mp.weixin.qq.com/s/vUUqkzwpcAqz6SjWR33Hfw</link><description></description><content:encoded><![CDATA[抓住质量管理“牛鼻子“，你在哪一段？]]></content:encoded><pubDate>Wed, 14 Apr 2021 16:49:28 +0800</pubDate></item><item><title>条件激活成为新宠：辉瑞开发小分子调控活性的Cond CAR-T</title><link>https://mp.weixin.qq.com/s/AISUduwNuzb69GWWuNUJhA</link><description></description><content:encoded><![CDATA[条件激活成为新宠：辉瑞开发小分子调控活性的Cond CAR-T]]></content:encoded><pubDate>Tue, 13 Apr 2021 14:08:11 +0800</pubDate></item><item><title>火热报名中 | 2021PVcon生物制品安全与工艺大会</title><link>https://mp.weixin.qq.com/s/iBal_kGpWbJTSPkzcvDulw</link><description></description><content:encoded><![CDATA[火热报名中 | 2021PVcon生物制品安全与工艺大会]]></content:encoded><pubDate>Tue, 13 Apr 2021 14:08:11 +0800</pubDate></item><item><title>国内第二家，君实PD-1尿路上皮癌获NMPA批准上市</title><link>https://mp.weixin.qq.com/s/uuaCme3jDrzcrSWWabGeEQ</link><description></description><content:encoded><![CDATA[国内第二家，君实PD-1尿路上皮癌获NMPA批准上市]]></content:encoded><pubDate>Tue, 13 Apr 2021 14:08:11 +0800</pubDate></item><item><title>药企福利·免费注册进行时！国内首个聚焦生物药质量领域的千人大会！</title><link>https://mp.weixin.qq.com/s/7RYZFijt_NnAoGcY0OeQ4A</link><description></description><content:encoded><![CDATA[药企福利·免费注册进行时！国内首个聚焦生物药质量领域的千人大会！]]></content:encoded><pubDate>Tue, 13 Apr 2021 14:08:11 +0800</pubDate></item><item><title>五大治疗性药物递送技术的进阶之路</title><link>https://mp.weixin.qq.com/s/3jFx1YT104xSLLHu8-cc8g</link><description></description><content:encoded><![CDATA[五大治疗性药物递送技术的进阶之路]]></content:encoded><pubDate>Mon, 12 Apr 2021 14:21:50 +0800</pubDate></item><item><title>今晚7点| 大分子CMC开发和生产的策略和进展</title><link>https://mp.weixin.qq.com/s/2xOApmgfby1GQFTCz1V_ZQ</link><description></description><content:encoded><![CDATA[今晚7点| 大分子CMC开发和生产的策略和进展]]></content:encoded><pubDate>Mon, 12 Apr 2021 14:21:50 +0800</pubDate></item><item><title>百济神州在美国癌症研究协会（AACR）2021年年会上公布Sitravatinib联合百泽安®的临床数据</title><link>https://mp.weixin.qq.com/s/2czmANxEVMIVwJNqSUh-Ig</link><description></description><content:encoded><![CDATA[百济神州在美国癌症研究协会（AACR）2021年年会上公布Sitravatinib联合百泽安®的临床数据]]></content:encoded><pubDate>Mon, 12 Apr 2021 14:21:50 +0800</pubDate></item><item><title>肿瘤免疫ADC</title><link>https://mp.weixin.qq.com/s/38Kz5pVdIt8hryo-hHmWxw</link><description></description><content:encoded><![CDATA[肿瘤免疫ADC]]></content:encoded><pubDate>Mon, 12 Apr 2021 08:00:37 +0800</pubDate></item></channel></rss>